Hedge Fund Titans Bet Big on Drugmaker Shire’s Success
John Paulson, Dan Loeb, and other prominent Investors move into an industry in flux.
Bailey McCannDecember 8, 2016
Illustration by Renaud Vigor.For the past few years, Shire has been defined by two things: popular niche drugs and failed M&A. That changed in June of this year, when the Irish-based drugmaker pulled off
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.